News
Hirschfield, G. M. et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148, 751–761 (2015).
The MND ANA pattern is immunomorphologically characterized by the staining of 3–20 dots of variable size distributed throughout the cell nucleus, but sparing the nucleoli and the mitoses (Figure ...
Liver Cirrhosis is a serious medical condition that can affect anyone’s life drastically. The good news is that with advancements in medical science and diagnostic technology, it can be treated ...
The government is planning to strengthen institutions to perform liver transplants in Bangladesh. Preparations are underway to initiate the procedure at two institutions– Birdem General Hospital and ...
In post-necrotic cirrhosis, the liver has nodules, or fibrous areas of tissue, more than 3 millimeters (mm) wide. If scar tissue builds up, it cannot work properly. This can lead to symptoms such ...
4d
Health on MSNWhat Is a Hepatologist?Medically reviewed by Jay N. Yepuri, MD A hepatologist is a doctor who specializes in diagnosing and treating liver and biliary system conditions, like fatty liver disease, cirrhosis (severe scarring) ...
KOCHI: Aswathi, a native of Anakkulam in Idukki, donated a portion of her liver to save her 9-month-old son, Edwin, who was ...
The Primary Biliary Cirrhosis Ursodiol plus Methotrexate or its Placebo Study (PUMPS)—an NIH-funded multicenter US trial of 265 patients randomized to either UDCA plus methotrexate or UDCA plus ...
According to the latest study from BCC Research, the "Liver Disease Treatments: The Global Market" is projected to increase from $46.0 ...
THIS YEAR, the vibrant city of Amsterdam, the Netherlands played host to the European Association for the Study of ...
Primary billiary cholangitis, or PBC, is a chronic disease that gradually damages the bile ducts, and eventually your liver. You may also hear it called primary billiary cirrhosis. Your bile ducts ...
FDA approves Ipsen's Iqirvo for primary biliary cholangitis, ending a 10-year hiatus in new therapies for the rare cholestatic liver disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results